List of questions
What are the barriers to adoption of point of care tests?
Community/Primary care versus Secondary care setting in testing and early diagnosis.
what unique issue is not being funded in relation to AI/AMR
IUK can provide funding in the development of AMR and needs to understand where to best any funds its may have available
What is the best way to get proteins into the cytoplasm of Gram negative or Gram positive bacteria?
Also interested in increasing the efficiency of entry of small molecule antibiotics
What disruptive therapeutic or technology approaches would allow us to better treat antibiotic-resistant Pseudomonas aeruginosa and Acinetobacter baumannii infections?
New treatments to treat Pseudomonas and Acinetobacter infections have proven to be particularly challenging. Both bacteria species represent serious unmet needs in the AMR area. New approaches are therefore urgently needed to address the current and future therapeutic gaps for these important bacterial pathogens.